Recruiting
Phase 3

ASI-02 & Saline

Sponsor:

Agitated Solutions, Inc.

Code:

NCT06938347

Conditions

Right-To-Left Shunt

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Agitated Saline SoC

ASI-02

Study Details

Brief summary:

This is a phase 3, multicenter, open-label, blinded, crossover trial in which each participant will undergo a randomized sequence of ASI-02 and agitated saline standard of care (SoC) via a saline contrast transthoracic echocardiogram (TTE) study.

Conditions

Right-To-Left Shunt

Study ID

NCT06938347

Start date

Nov 5, 2025

Status verified date

Jul, 2026

Completion date

Sep, 2026

Anticipated

Primary completion date

Sep, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

1. Patient is clinically indicated for a saline contrast TTE study with a suspected right-to-left shunt
2. Patient must be at least 18 years of age inclusive, at the time of signing the informed consent
3. Able to communicate effectively with trial personnel

Exclusion Criteria:

1. Female patients who are pregnant or lactating. All women of child-bearing potential (WOCBP) must have a negative urine pregnancy test at screening regardless of contraceptive use history
2. WOCBP are excluded unless they have been using an adequate and medically approved method of contraception to avoid pregnancy for at least 1 month prior to ASI-02 dose administration
3. Allergy to polysorbate 80 (PS-80)
4. American Society of Anesthesiologists (ASA) physical status classification IV, V, or VI, except that participants with ASA physical status IV due solely to recent suspected transient ischemic attack or cerebrovascular accident are eligible for inclusion
5. Current illness or pathology that in the opinion of the investigator would prevent undergoing investigational product administration due to a significant safety risk to the patient
6. Uncontrolled arterial hypertension (defined as systolic blood pressure ≥ 200 mmHg or diastolic blood pressure ≥ 110 mmHg) or arterial hypotension (defined as systolic blood pressure ≤ 90 mmHg)
7. Unstable cardiovascular status defined as:

1. myocardial infarction or unstable angina pectoris within 6 months prior to procedure day
2. symptomatic valvular heart disease or moderate to severe stenotic valvular heart disease
3. clinically significant congenital heart defects (excluding an atrial septal defect \[ASD\], patent foramen ovale \[PFO\], or pulmonary arteriovenous malformation \[PAVM\])
4. current uncontrolled cardiac arrhythmias causing clinical symptoms requiring medical intervention or hemodynamic compromise
5. acute pulmonary embolus or pulmonary infarction
6. acute myocarditis or pericarditis
7. acute aortic dissection
8. untreated atrial fibrillation
8. Any major surgery within 30 days prior to screening
9. Participation in any investigational drug, device, or placebo study within 30 days prior to screening
10. Vulnerable adult participant populations (e.g., incarcerated or cognitively challenged adults)

Study Design

Enrollment

300 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Standard of Care to ASI-02 TTE Study

Participants will be allocated to a saline contrast echocardiography study with agitated saline SoC, followed by a saline contrast echocardiography study with ASI-02.

experimental: ASI-02 to Standard of Care TTE Study

Participants will be allocated to a saline contrast echocardiography study with ASI-02, followed by a saline contrast echocardiography study with agitated saline SoC.

Interventions

Agitated Saline SoC

The recommended initial dose of agitated saline SoC is approximately 10 mL of saline containing approximately 1 mL of air, per institutional policy, rapidly mixed (approximately 10-20 presses) to manufacture microbubbles. No additives are allowed to the saline, including blood, dextrose, or bacteriostatic saline.

ASI-02

Each injection shall utilize one (1) ASI-02 product connected to one (1) pre-filled 10 mL 0.9% sodium chloride (saline) syringe. The ASI-02 investigational product will be connected to a standard luer lock connector and administered in its entirety. The intravenous bolus injected dose of ASI-02 is 9 mL of saline and 1 mL of air.

Primary outcome measure

  • Positive percentage agreement (PPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC [ Time Frame: Procedure through 24- to 48-hour participant follow-up visit ]
  • Negative percentage agreement (NPA) of ASI-02 for detecting right-to-left shunt versus agitated saline SoC [ Time Frame: Procedure through 24- to 48-hour participant follow-up visit ]

Central Contacts and Locations

Locations

Northwestern University

Recruiting

Chicago, Illinois, United States, 60611

Principal Investigator:

Akhil Narang, MD

AH Illinois Masonic Center

Recruiting

Chicago, Illinois, United States, 60657

Principal Investigator:

Sorin Danciu, MD

Mayo Clinic

Recruiting

Rochester, Minnesota, United States, 55905

Principal Investigator:

Sunil Mankad, MD

CentraCare

Recruiting

Saint Cloud, Minnesota, United States, 56303

Principal Investigator:

Timothy Schuchard, MD

Jackson Heart Clinic

Recruiting

Jackson, Mississippi, United States, 39216

Principal Investigator:

William Crowder, MD

NYU Langone Health

Recruiting

New York, New York, United States, 10016

Principal Investigator:

Daniel Bamira, MD

Aurora St. Lukes Medical Center

Recruiting

Milwaukee, Wisconsin, United States, 53215

Principal Investigator:

Renuka Jain, MD

Toronto General

Recruiting

Toronto, Canada, M5G 2C4

Principal Investigator:

Wendy Tsang, MD

More Information

Sponsor

Agitated Solutions, Inc.

Last update posted

Jul 6, 2026

Last verified

Jul, 2026

Keywords

  • Saline Contrast
  • Saline Contrast Transthoracic Echocardiogram
  • Transthoracic Echocardiogram
  • Agitated Saline Standard of Care
  • Echocardiogram
  • Transpulmonary Shunt

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Agitated Solutions, Inc. on 2026-07-06.